


Project Name	Country: Indonesia, Thailand, Vietnam / Demonstration Project for Establishing a Japanese-Led De Facto Standard Remote Healthcare DX Platform Centered on Prosthetics and Orthotics Manufacturing DX		
Company Name	Paramount Bed Co., Ltd.	Company Size	SME / Other than SME
Category	Category 1 / Category 2 / Category 3	Project Field	GX / DX / Economic Security
Total Project Expenses/Total Subsidy Expenses/ Subsidy Application Amount	1.17 billion yen / 0.58 billion yen / 0.58 billion yen		

Project Outline
【Project Scheme】



【Outline】

This project deploys Japan-originated remote healthcare DX in ASEAN to enhance healthcare delivery and establish a sustainable business model. It builds a hospital-collaborative remote healthcare DX platform centered on orthotics and prosthetics manufacturing DX, adapted to local regulations and operations.

【Key Technologies and Demonstrations】


Primary technology: orthotics and prosthetics manufacturing DX (Instalimb), integrating 3D scanning, AI modeling, and 3D printing. Demonstrations in Indonesia and Thailand will validate deployment, operation, and scalability across diverse regulatory environments, while assessing expansion potential in ASEAN.

【Project Size】

JPY 3.4 billion (5-year cumulative)

【Schedule】

- FY2026: Start technology transfer and deployment; build operation frameworks
- FY2027: Validate operations and promote standardization
- FY2028: Expand to adjacent domains; develop de facto standard
- FY2029: Commercialize and scale across ASEAN



Concept: Hospital-Collaborative Remote Healthcare DX Platform



Primary Technology:
Orthotics and Prosthetics Manufacturing DX

Resulting benefits to Japan 【Points that this project contributes to innovation creation in Japan】

This project will accelerate global deployment of Japan-originated remote orthotics and prosthetics manufacturing DX, generating sustained demand for 3D printers, materials, software, and related services. Revenue expansion of approx. JPY 3.4 billion (5-year cumulative), mainly in Indonesia and Thailand, is expected, supporting domestic manufacturing and operations. Standardized know-how will be fed back to Japan, advancing healthcare DX and productivity. Expansion in ASEAN will also enhance global recognition of Japanese medical technologies and create broader spillover effects.